Compare iShares MSCI Malaysia ETF (EWM) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Natera Inc. Common Stock — how do they compare? iShares MSCI Malaysia ETF trades at $26.86 (market cap $242.56M), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 235.1× iShares MSCI Malaysia ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 68 Days and Natera Inc. Common Stock for 0 Days on average.
| EWM | NTRA | |
|---|---|---|
Market Cap | $242.56M | $57.03B |
Volume | 361,558 | 1,131,157 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $425.64 |
52-Week Low | $25.47 | $179.42 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM trades at $26.96, up 0.63% today, but technical indicators signal a bearish trend with moving averages and ADX suggesting selling pressure. Key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity. Recent news highlights external risks, such as regional haze-related disruptions affecting operations in Malaysia, which could impact investor confidence.
The outlook remains cautious due to weak technicals and limited fundamental data. Risks include environmental disruptions and market volatility. Investment opportunities hinge on upcoming financial disclosures to validate growth prospects, while current sentiment leans bearish amid uncertainty.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
